Lamin A/C Mouse anti-Human, Mouse, Rat, Clone: Jol3, Invitrogen
Mouse Monoclonal Antibody
Manufacturer: Invitrogen MA15820
MA1-5820 reacts with human dermal fibroblasts in immunocytochemistry. Other cell/tissue types have not been tested in this application. It reacts with human, mouse and rat samples in Western blot. This antibody recognizes the common tail domain of Lamin A+C, epitope aa 464-572.Nuclear lamins form a network of intermediate-type filaments at the nucleoplasmic site of the nuclear membrane. Two main subtypes of nuclear lamins can be distinguished, i.e. A-type lamins and B-type lamins. The A-type lamins comprise a set of three proteins arising from the same gene by alternative splicing, i.e. lamin A, lamin C and lamin Adel 10, while the B-type lamins include two proteins arising from two distinct genes, i.e. lamin B1 and lamin B2. Recent evidence has revealed that mutations in A-type lamins give rise to a range of rare but domit genetic disorders, including Emery-Dreifuss muscular dystrophy, dilated cardiomyopathy with conduction-system disease and Dunnigan-type familial partial lipodystrophy. In addition, the expression of A-type lamins coincides with cell differentiation and as A-type lamins specifically interact with chromatin, a role in the regulation of differential gene expression has been suggested for A-type lamins.
|Recombit bacterially expressed full length protein|
|Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.|
|16905, 4000, 60374|
|ChIP assay, Immunocytochemistry, Immunofluorescence, Western Blot|
|tissue culture supernatant with 0.1% sodium azide|
|P02545, P48678, P48679|
|Prelamin-A/C, Lamin-A/C, 70 kDa lamin, Renal carcinoma antigen NY-REN-32, LMNA, LMN1|
|Human, Mouse, Rat|
We continue to work to improve your shopping experience and your feedback regarding this content is very important to us. Please use the form below to provide feedback related to the content on this product.
Your feedback has been submitted. Fisher Scientific is always working to improve our content for you. We appreciate your feedback.Ok